Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Immersion Pulmonary Edema (IPE), Swimming Induced Pulmonary Edema (SIPE)
Interventions: Sildenafil; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infections, Respiratory Tract
Interventions: GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Spinal Cord Injuries
Interventions: Daily acute intermittent hypoxia, Walking + tSTIM; Other · Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Jacksonville, Florida • Cambridge, Massachusetts

Conditions: Exercise Physiology, Nutritional Supplementation
Interventions: Caffeine, L-Citrulline, Exogenous Ketone (Beta-Hydroxybutyrate), placebo beverage; Dietary Supplement · Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes, Obesity
Interventions: Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies; Behavioral · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 59 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Glioma
Interventions: PEG-interferon alfa-2b, Thalidomide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Goserelin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 46 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melphalan Autologous Transplant
Interventions: Specialized menu, Standard of care menu, Self report dietary intake worksheet, Post study questionnaire; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pre-Symptomatic Type 1 Diabetes
Interventions: Golimumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Charlottesville, Virginia

Conditions: Brain Tumor, Glioblastoma
Interventions: MRI/MRS Scan; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Carcinoma
Interventions: Letrozole; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 40 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Sacramento, California

Conditions: Hearing Impairment
Interventions: Investigational Software; Device
Lead sponsor: Cochlear; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Lone Tree, Colorado

Conditions: Stroke, Cerebral Ischemia
Interventions: Argatroban; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fibroids, Uterine, Fluid Deficit, Hysteroscopy / Methods
Interventions: Misoprostol Tabets, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Morbid, Bariatric Surgery Candidate
Interventions: Surgery; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Stem Cell Transplant, Allogeneic
Interventions: CliniMACS CD34 Reagent system; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 70 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Anxiety
Interventions: Bedside Entertainment and Relaxation Theater (BERT); Device
Lead sponsor: Yale University; Other
Eligibility: 4 Years to 14 Years
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: BRCA Hereditary Ovarian Carcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Uterine Lavage, Archive Sample, Survey Administration; Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Endometriosis, Fibroids, Adenomyosis, Pelvic Pain, Abnormal Uterine Bleeding, Adnexal Mass, Minimally Invasive Gynecologic Surgery, Hysterectomy, Myomectomy, Ovarian Cystectomy, Adnexal Surgery
Interventions: educational video; Other
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Infertility
Interventions: Embryo cryopreservation, Fresh blastocyst transfer; Procedure
Lead sponsor: Fertility Center of Las Vegas; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Infant Obesity, Parenting, Feeding Behavior
Interventions: Responsive Feeding Training; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Months to 9 Months
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 18 more

Conditions: Gorham Disease, Lymphatic Diseases, Lymphangiomatosis
Interventions: Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL), Heavy Weighted T2 Imaging (T2W), Lymph Node Access; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Prevention and Treatment of Immersion Pulmonary Edema

Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

Low Oxygen Therapy to Enhance Walking Recovery After SCI.

Effects of Pre-Run Nutritional Supplements During a Fixed-Pace 5 km Treadmill Run

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

Implementation of a Nutritional Tool During Melphalan Autologous Transplant to Improve Caloric and Protein Intake

A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

Measuring Non-Enhancing Glioblastoma Progression

Letrozole as a Treatment of Endometrial Cancer

A Study Examining Acceptability of Auditory Implant Fitting Software Technologies

Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

Cognitive Impairment, Obesity, and the Effects of Bariatric Surgery

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

Audiovisual Interactive Games to Alleviate Pediatric Perioperative Anxiety

Uterine Lavage to Detect Ovarian Cancer Risk

Impact of Educational Videos on Pre-operative Anxiety

Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients

Learning to Love Mealtime Together

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Imaging of Lymphatic Anomalies